Archive for July 28th, 2012

Pipeline profiles of recent Biotech Initial Public Offerings – DRTX TSRO HPTX MACK CCXI CEMP

Jul 28, 2012 No Comments by

Hyperion Therapeutics, Inc (NASDAQ:HPTX) – Initial public offering July 2012.  PIPELINE Ravicti: PDUFA date October 23, 2012 for urea cycle disorders. Phase 2 trial completed for hepatic encephalopathy, or HE. End of Phase 2 meeting with the FDA planned for 4Q 2012. Durata Therapeutics Inc (NASDAQ:DRTX) – Initial public offering July 2012.  PIPELINE Dalbavancin: Phase 3 trial for the treatment of patients with acute bacterial skin and skin […]

Articles Read more

SLXP PGNX issued CRL. FURX resubmits NDA. ARIA initiates Phase 3 CML. CTIC confirms possibility of reverse split + ACUR

Jul 28, 2012 4 Comments by

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today received a Complete Response Letter (CRL) for its Supplemental New Drug Application (sNDA) for RELISTOR injection for subcutaneous use for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. The CRL requests additional clinical data. Salix and Progenics intend to request an End-of-Review meeting with the Division […]

Daily News Read more